Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company developing immunotherapies, has announced promising results from its Phase 1b study of azer-cel, an off-the-shelf, allogeneic CAR T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results